Intravenous Ketorolac for Postoperative Pain in Laparoscopic Donor Nephrectomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00765232 |
Recruitment Status :
Completed
First Posted : October 2, 2008
Results First Posted : January 27, 2012
Last Update Posted : January 27, 2012
|
Sponsor:
Mayo Clinic
Information provided by:
Mayo Clinic
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment |
Conditions |
Nephrectomy Laparoscopic Donor Nephrectomy |
Interventions |
Drug: Ketorolac Drug: Placebo |
Enrollment | 111 |
Participant Flow
Recruitment Details | Patients were recruited from October 2008 to November 2010. |
Pre-assignment Details |
Arm/Group Title | Ketorolac | Placebo |
---|---|---|
![]() |
90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery. | 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery. |
Period Title: Overall Study | ||
Started | 57 | 54 |
Completed | 57 | 54 |
Not Completed | 0 | 0 |
Baseline Characteristics
Arm/Group Title | Ketorolac | Placebo | Total | |
---|---|---|---|---|
![]() |
90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery. | 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery. | Total of all reporting groups | |
Overall Number of Baseline Participants | 57 | 54 | 111 | |
![]() |
[Not Specified]
|
|||
Age Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||
Number Analyzed | 57 participants | 54 participants | 111 participants | |
43 (11) | 43 (13) | 43 (12) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||
Number Analyzed | 57 participants | 54 participants | 111 participants | |
Female |
23 40.4%
|
33 61.1%
|
56 50.5%
|
|
Male |
34 59.6%
|
21 38.9%
|
55 49.5%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Mitchell R. Humphreys MD |
Organization: | Mayo Clinic |
Phone: | 480-301-8000 |
EMail: | humphreys.mitchell@mayo.edu |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Mitchell R. Humphreys, M.D., Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT00765232 |
Other Study ID Numbers: |
08-000747 LDN |
First Submitted: | September 30, 2008 |
First Posted: | October 2, 2008 |
Results First Submitted: | November 18, 2011 |
Results First Posted: | January 27, 2012 |
Last Update Posted: | January 27, 2012 |